^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NCAM1 expression

    i
    Other names: NCAM1, CD56, NCAM, Neural cell adhesion molecule 1
    Entrez ID:
    4684
    Related biomarkers:
    Expression
    18d
    The Role of CD56, HBME-1, and CK19 Immunohistochemical Markers in the differential Diagnosing of Thyroid Neoplasms. (PubMed, Niger Med J)
    The specificity of CD56, CK19, and HBME-1 in diagnosing follicular thyroid carcinoma (FTC) from FA was 84.21%, 85%, and 84.21%, respectively. Our study highlights the diagnostic utility of CD56, CK19, and HBME-1 in thyroid neoplasms incorporating these markers into routine diagnostic panels can significantly enhance the accuracy and reliability of thyroid malignancy assessments.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • KRT19 (Keratin 19)
    |
    NCAM1 expression
    25d
    Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma with aberrant CD56 expression: a rare case report. (PubMed, Postepy Dermatol Alergol)
    No abstract available
    Journal
    |
    CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    28d
    A Case of Abscessing Ileocecal Monomorphic Epitheliotropic Intestinal T-cell Lymphoma. (PubMed, Cureus)
    The proliferation index Ki-67 was evaluated as high, being positive in more than 70% of the tumor cells. The patient died 39 days after the initial onset of symptoms.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1)
    |
    CD8 expression • NCAM1 expression
    1m
    CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia. (PubMed, Heliyon)
    Moreover, this increase disappears in CML patients after treatment with tyrosine kinase inhibitors when the curative effect was satisfactory. We conclude that an increase in the proportion of CD56briCD38+ neutrophil subsets exceeding 2.0 % of total neutrophils serves as a highly sensitive and specific flow cytometry marker, enabling rapid and accurate identification of CML.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    BCR-ABL1 fusion • CD38 expression • NCAM1 expression
    1m
    Immunomodulatory properties of extracellular vesicles isolated from bone marrow of patients with neuroblastoma: role of PD-L1 and HLA-G. (PubMed, Front Immunol)
    Finally, a high expression of CD56, HLA-G and PD-L1 on BM-derived EVs may represent a good prognostic factor. We described the presence of HLA-G and PDL1-bearing EVs in the BM of NB patients, which may represent a mechanism performed by resident BM cells to counteract the inflammation occurring in the BM microenvironment of NB patients.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immunomodulating
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • NCAM1 (Neural cell adhesion molecule 1) • CSF2 (Colony stimulating factor 2) • HLA-G (Major Histocompatibility Complex, Class I, G)
    |
    NCAM1 expression
    2ms
    Expanding the Spectrum of GLI1-rearranged Neoplasms of the Gastrointestinal Tract to Include Monophasic Keratin-positive Epithelial Neoplasms. (PubMed, Am J Surg Pathol)
    Diffuse strong nuclear cyclin D1 expression was seen in both cases, and conversely, strong cyclin D1 staining was only seen in 5.4% (4/74) of well-differentiated neuroendocrine tumors tested. These 2 GI tract neoplasms highlight a widened spectrum of GLI1-rearranged tumors, now including monophasic epithelial neoplasms with diffuse keratin expression.
    Journal
    |
    CCND1 (Cyclin D1) • GLI1 (GLI Family Zinc Finger 1) • NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
    |
    CCND1 expression • NCAM1 expression
    2ms
    CD56 does not contribute to the anti-tumor, tissue homing, and glycolytic capacity of human NK cells. (PubMed, J Leukoc Biol)
    Lastly, CD56 does not alter expanded NK cell in vivo tissue trafficking. Our results indicate that while CD56 expression could be used to indicate a hyper-functional state of NK cells, it does not directly influence the anti-tumor functions of expanded NK cells.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    2ms
    NCAM and attached polysialic acid affect behaviors of breast epithelial cells through differential signaling pathways. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    Modification of polySia attached to NCAM modulates cell adhesion and promotes cell motility through activation of the EGFR/STAT3 pathway. These observations contribute to clarifying the molecular mechanisms by which polysialic acid and its major substrate, NCAM, modulate cell behaviors, and highlight the significance of increased polysialylated expression on NCAM during EMT and tumor development.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • SNAI2 (Snail Family Transcriptional Repressor 2)
    |
    NCAM1 expression
    2ms
    Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review. (PubMed, Turk J Pediatr)
    HLH can serve as the initial manifestation of ANKL. Leukemia cells of ANKL have significant variations in the morphology and mainly express CD56. Intensive combination chemotherapy based on pegaspargase and anthracyclines may be considered for ANKL.
    Review • Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    |
    Oncaspar liquid (pegaspargase)
    3ms
    CD56-targeted in vivo genetic engineering of natural killer cells mediates immunotherapy for acute myeloid leukemia. (PubMed, Nanoscale)
    The in vitro NK (EzH2-) cells and pEzH2@CSNPs@CD56 reduced splenomegaly while immunophenotyping revealed in vivo downregulation of the c-Kit+ leukemia stem cell population along with upregulation of the differentiation markers CD11b and Gr-1 in the peripheral blood and bone marrow of AML1-ETO9a-induced xenograft nude mice. CD56+CD3- and CD56+CD38+ cell populations were significantly increased in the peripheral blood and bone marrow, which indicated NK cell-mediated AML cell killing took place suggesting that use of pEzH2@CSNPs@CD56 is a safe and viable strategy for NK cell-mediated anti-AML immunotherapy.
    Preclinical • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • NCAM1 (Neural cell adhesion molecule 1) • ITGAM (Integrin, alpha M) • NKG2D (killer cell lectin like receptor K1)
    |
    NCAM1 expression
    4ms
    Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia. (PubMed, J Hematol)
    The FC analysis of the peripheral blood allowed the rapid characterization of a non-hematological neoplastic cell population, circulating at unusually high frequency and mimicking an acute myeloid leukemia. The FC detection of CD45-negative cell populations in peripheral blood, bone marrow or lymph node aspirate should prompt the setup of an immunophenotyping panel including EpCAM, CD9, CD56 and CD117, to allow for a rapid and accurate identification of ectopic malignant epithelial cells.
    Journal • IO biomarker • Tumor cell
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • SDC1 (Syndecan 1) • CD9 (CD9 Molecule) • TFRC
    |
    CD38 positive • NCAM1 expression • CD9 expression • SDC1 positive • EPCAM expression
    4ms
    Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation. (PubMed, Am J Clin Pathol)
    The MCs in AML-MC cases are characterized by dim CD45, low side scatter, CD34 and CD123 positivity, and uniform and increased CD38 expression. Flow cytometry is an excellent tool for identifying AML-MC cases.
    Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    CD38 expression • CD123 positive • NCAM1 expression • CD34 positive
    8ms
    Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). (PubMed, Future Oncol)
    Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months)...Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • mTOR (Mechanistic target of rapamycin kinase) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule) • FUT4 (Fucosyltransferase 4)
    |
    PD-L1 expression • NCAM1 expression • CD4 expression • CD4 underexpression • NCAM1 overexpression
    |
    Opdivo (nivolumab)
    9ms
    Primary cutaneous extranodal natural killer/T cell lymphoma with delayed expression of CD56. (PubMed, Eur J Dermatol)
    No abstract available
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    9ms
    A TEMPORAL DEVELOPMENTAL MAP SEPARATES HUMAN NK CELLS FROM NON-CYTOTOXIC ILCS THROUGH CLONAL AND SINGLE-CELL ANALYSIS. (PubMed, Blood Adv)
    Cross-referencing gene signatures of culture derived NK cells and other non-cytotoxic ILCs with publicly available datasets validated that these in vitro stages highly resemble transcriptional profiles of respective in vivo ILC counterparts. Finally, by integrating RNA-velocity and gene-network analysis through SCENIC we unravel a network of coordinated and highly dynamic regulons driving the cytotoxic NK cell program, as a guide map for future studies on NK cell regulation.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • KLRB1 (Killer Cell Lectin Like Receptor B1) • KLRD1 (Killer Cell Lectin Like Receptor D1)
    |
    NCAM1 expression
    10ms
    Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023
    Enrollment open • Trial initiation date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    10ms
    Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, PETHEMA Foundation
    New P2 trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    11ms
    Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation. (PubMed, Diagn Pathol)
    The killing capacity of infiltrating CLs in PTC differed between tumor tissues and paracancerous tissues. In cases with CCLNM, higher expression of CD16-CD56+G+ NK cells in tumor tissues may be associated with a high risk of lymph node metastasis.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • GZMB (Granzyme B)
    |
    BRAF V600E • BRAF V600 • NCAM1 expression
    11ms
    Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene. (PubMed, J Pediatr Hematol Oncol)
    Transcriptome RNA sequencing is required for the detection of the CBFA2T3-GLIS2 fusion gene and for proper risk-based allocation of pediatric patients with AML in future clinical strategies. Haplo-HSCT with posttransplant cyclophosphamide-based conditioning may improve survival in children with AMKL harboring the fusion gene.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2)
    |
    NCAM1 expression • CBFA2T3 - GLIS2 fusion
    |
    cyclophosphamide
    11ms
    K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3. (PubMed, Cell Commun Signal)
    Western blot analyses revealed pronounced reduction of E-cadherin and NCAM in the Akt3-kd cells, whereas Akt1 and Akt2 depletion upregulated E-cadherin, especially in H23 lung carcinoma cells. In summary, we identified oncogenic K-Ras4B as a key regulator of PI3-Kα-Akt signaling and Akt3 as a crucial regulator of K-Ras4B-induced modulation of E-cadherin and NCAM expression and localization.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDH1 (Cadherin 1) • RAS (Rat Sarcoma Virus) • NCAM1 (Neural cell adhesion molecule 1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    KRAS mutation • RAS mutation • NCAM1 expression • CDH1 expression • AKT2 expression • KRAS V12 • KRAS expression
    11ms
    Cleaved Leukemic Blast Cells, Vacuolation and Pseudopodia-like Cytoplasmic Projections in Acute Myeloid Leukemia with TLS::ERG. (PubMed, Turk J Haematol)
    Our present case presented partial expression of CD56 and bone marrow reexamination showed continuous CR for three months, but due to economic reasons, he did not continue follow-up examination, and the efficacy could not be evaluated. In brief, this case reminds us to recognize atypical morphologic features of clefted leukemic blasts and pseudopodia-like cytoplasmic projections in some subtypes of leukemias.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    12ms
    Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry. (PubMed, Fetal Pediatr Pathol)
    CD56 is a potential negative prognostic marker. These findings suggest that CD30 and CD56 targeted therapies could be potential therapeutic targets for LBL patients.
    Retrospective data • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • NCAM1 (Neural cell adhesion molecule 1)
    |
    TNFRSF8 expression • NCAM1 expression • NCAM1 positive
    12ms
    The Significance of Insulinoma-Associated Protein 1 in the Pathological Diagnosis of Small-Cell Lung Cancer in Biopsy Specimens. (PubMed, Int J Surg Pathol)
    The sensitivity of INSM1 expression was significantly higher than that of CHGA (95% vs 50%, P = .000), but there was no statistically significant difference in the specificity of INSM1, SYP, CHGA, and CD56 expression (100% vs 94% vs 98% vs 92%, respectively, P = .241, 1.000, .126). INSM1 antibody shows high sensitivity and specificity in the expression of SCLC and serves as a reliable immunohistochemical marker in the clinicopathological diagnosis of SCLC in biopsy specimens.
    Journal • Biopsy
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin) • CHGA (Chromogranin A) • INSM1 (INSM Transcriptional Repressor 1)
    |
    NCAM1 expression
    1year
    Aberrant Expression of CD56 in Metastatic Malignant Melanoma. (PubMed, Cutis)
    No abstract available
    Journal • Metastases
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression
    1year
    CD56 polysialylation promotes the tumorigenesis and progression via the Hedgehog and Wnt/β-catenin signaling pathways in clear cell renal cell carcinoma. (PubMed, Cancer Cell Int)
    Our findings demonstrate that the oncogenic function of CD56 polysialylation plays a vital role in the tumorigenesis and progression of ccRCC, implying that targeting PSA-CD56 might be a feasible treatment target for ccRCC.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 expression • NCAM1 overexpression
    1year
    Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung. (PubMed, Cancers (Basel))
    Musashi-1 also tended to show more diffuse and intense staining, especially in LCNEC, with more cases staining > 10% than any other existing markers (Musashi-1, 77%; INSM1, 45%; chromogranin A, 34%; synaptophysin, 41%; and CD56, 66%). In conclusion, we identified Musashi-1 as a novel immunohistochemical staining marker to aid in the diagnosis of lung NEC.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
    |
    NCAM1 expression
    1year
    CLINICAL AND PATHOLOGICAL EVALUATION OF INSM1 IMMUNOHISTOCHEMICAL EXPRESSION IN GASTRIC NEUROENDOCRINE TUMORS (IGICC 2023)
    In our study, 80 patients were initially included, but 8 patients had to be excluded due to missing data.Among the remaining 72 patients, 46 were female, and 26 were male.The average age of the participants was 48.5±14.5 years, ranging from 20 to 82 years.The average tumor size was 4.7±2.2 mm, with a range of 1 to 18 mm. The average Ki-67 mitotic index was found to be 1.8±0.7 in the study. Histologically, grade 1 tumors were the most common, accounting for 75% of cases, while grade 3 tumors were the least common, representing only 1.4% of cases.
    Clinical
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin) • INSM1 (INSM Transcriptional Repressor 1)
    |
    NCAM1 expression
    1year
    Diagnostic Challenges in the Leukemia Phase of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Involvement: A Clinical and Pathological Study (ASH 2023)
    Only one cycle of decitabine + CAG was given and 5 months later, the disease progressed to the leukemia phase...The latter case had ASXL1 and TET2 mutations detected by NGS analysis, achieved complete remission after receiving venetoclax + azacitidine for one cycle, followed by intermittent venoclax +demethylation agent or low-dose chemotherapy maintenance treatment and live for more than two years now... BPDCN without skin lesions is clinically rare, and its diagnosis is challenging. Comprehensive immunophenotyping and cautious interpretation of immunohistochemistry results such as dim lysozyme expression are crucial. Venetoclax-containing regimens have shown promising therapeutic effects.
    Clinical
    |
    TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD36 (thrombospondin receptor) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NRP1 (Neuropilin 1) • SPN (Sialophorin) • TCL1A (TCL1 Family AKT Coactivator A) • ANPEP (Alanyl Aminopeptidase, Membrane) • CLEC4C (C-Type Lectin Domain Family 4 Member C) • MPO (Myeloperoxidase)
    |
    TP53 mutation • ASXL1 mutation • TET2 mutation • CD123 positive • NCAM1 expression • CD123 expression • CD4 expression • IDH2 mutation + TP53 mutation • IL3RA positive • NCAM1 positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    1year
    Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax (ASH 2023)
    NCAM1 expression is a marker of poor prognosis in ND AML patients treated with HMA+VEN. Knockout of NCAM1 in the OCI-AML2 cell line sensitized cells to VEN. Our data suggest that NCAM1 expression on AML blasts plays a biological role in promoting cellular resistance to VEN.
    Clinical • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • NCAM1 (Neural cell adhesion molecule 1) • ITGAM (Integrin, alpha M) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    TP53 mutation • KRAS mutation • FLT3-ITD mutation • IDH1 mutation • NCAM1 expression
    |
    Venclexta (venetoclax)
    1year
    Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas. (PubMed, Ann Diagn Pathol)
    Positive expression of Syn was associated with reduced PFS and OS, while positive CD56 expression was correlated with a shorter OS in HGNEC. The TNM stage was an independent risk factor that significantly influenced PFS and OS in patients with HGNEC. More studies are needed to make further progress in future treatment.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • SYP (Synaptophysin)
    |
    NCAM1 expression • NCAM1 positive
    1year
    HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration. (PubMed, Biomedicines)
    In HER-2-upregulated CRC tissues, CD4, CD8, CD19, CD68, CD11b, Ly6G, and CD56 expressions were elevated (0.70 ± 0.37 vs. 0.32 ± 0.17, p = 0.03; 0.22 ± 0.13 vs. 0.09 ± 0.06, p = 0.03; 0.31 ± 0.19 vs. 0.12 ± 0.08, p = 0.02; 1.05 ± 0.62 vs. 0.43 ± 0.21, p < 0.01; 1.34 ± 0.81 vs. 0.53 ± 0.23, p < 0.01; 0.50 ± 0.31 vs. 0.19 ± 0.10, p < 0.01; 1.26 ± 0.74 vs. 0.52 ± 0.24, p < 0.01). Furthermore, increased HER-2 expression was an independent risk factor for recurrence-free survival (RFS) in patients (p < 0.01, HR = 3.421); The increased expression of HER-2 and its relationship with immune cells will provide new insights for immunotherapy in CRC patients.
    Journal • IO biomarker • Immune cell
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • CD68 (CD68 Molecule) • ITGAM (Integrin, alpha M)
    |
    HER-2 positive • HER-2 expression • NCAM1 expression • EPCAM expression
    1year
    A Comparative Study of CD56 and Smooth Muscle Actin Expression in Basal and Squamous Cell Carcinomas. (PubMed, Am J Dermatopathol)
    CD56 and SMA, in addition to Bcl-2, favor BCC. Ki67 should also be included in the panel to demonstrate the proliferative activity.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • NCAM1 (Neural cell adhesion molecule 1)
    |
    BCL2 expression • NCAM1 expression
    1year
    BREAST TUMOR CHARACTERIZED BY THE PRESENCE OF TUMOR CELLS IN PERIPHERAL BLOOD MIMICKING MYELOID ACUTE LEUKEMIA: A CASE REPORT (SIE 2023)
    The flow cytometric analysis allowed to discover the non-hematological nature of this population, circulating at high level in peripheral blood. Aspirate smears revealed the presence of the same cells, and immunohistochemistry on bone marrow confirmed the massive infiltration of breast cancer cells, allowing to diagnose bone marrow metastases.
    Clinical • IO biomarker • Tumor cell
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • SDC1 (Syndecan 1) • CD9 (CD9 Molecule) • TFRC
    |
    ER positive • HER-2 negative • PGR positive • CD38 positive • NCAM1 expression • SDC1 positive
    1year
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. (PubMed, Br J Haematol)
    A trend towards improved OS and EFS with hypomethylating agent-venetoclax combination was observed in My-AML, but not Mo-AML. These findings define distinct progression of CMML and set the basis for future studies evaluating the role of phenotype-specific therapeutics.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule)
    |
    TP53 mutation • RAS mutation • TET2 mutation • SRSF2 mutation • CEBPA mutation • KIT expression • NCAM1 expression
    |
    Venclexta (venetoclax)
    1year
    Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters. (PubMed, Curr Probl Cancer)
    Increased burden of CTPCs was associated with presence of lytic lesions, plasmacytomas, Chr 1p32 deletion, expression of CD56 and CD81 on tumor cells and with failure to achieve very good partial response. The CNPCs were lower in patients with thrombocytopenia and with hypoalbuminemia. To best ot our knowledge, this is the first study from India on the relevance of circulating tumor plasma cells and the first study in the world to analyse the associations of circulating normal plasma cells in newly diagnosed patients of multiple myeloma. The study also highlights the utility of multi-parametric flow cytometry in identification and enumeration of circulating plasma cells.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • CD81 (CD81 Molecule)
    |
    NCAM1 expression
    1year
    Chronic Lymphoproliferative Disorder of Natural Killer Cells: Patient Characteristics, Laboratory Features, and Clinical Outcomes (ASH 2023)
    For first-line treatment, in addition to frequent steroid use, 16 pts (70%) received a methotrexate-based regimen, 6 (26%) received a cyclophosphamide-based regimen, and 1 (4%) received a cyclosporine-based regimen. In this large cohort of 45 pts, the majority had neutropenia and anemia, and approximately half required systemic treatment. Estimated median OS from diagnosis exceeded a decade for the entire cohort and was seven years after treatment initiation. Anemia was associated with a shorter TTFT, while increasing age and lack of CD94 expression were associated with worse OS.
    Clinical • Clinical data
    |
    CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • CD7 (CD7 Molecule) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2) • KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRD1 (Killer Cell Lectin Like Receptor D1)
    |
    CD8 expression • NCAM1 expression • CD7 expression
    |
    cyclophosphamide • methotrexate • cyclosporine
    1year
    Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma:Pathological Phenotype and Genetic Mutation Analysis of 12 Patients (ASH 2023)
    Our results show that MEITL is extremely rare, accounting for only 2.4% of all lymphomas involving the intestines. Patients with MEITL have a poor prognosis, with a median OS of less than six months. However, early elective surgery can significantly improve patient survival.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CREBBP (CREB binding protein) • BCOR (BCL6 Corepressor) • JAK1 (Janus Kinase 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • CD4 (CD4 Molecule) • EP300 (E1A binding protein p300) • JAK3 (Janus Kinase 3) • NCAM1 (Neural cell adhesion molecule 1) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • GZMB (Granzyme B) • SOCS1 (Suppressor Of Cytokine Signaling 1) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein)
    |
    KRAS mutation • NRAS mutation • TNFRSF8 expression • CD20 expression • CD8 expression • NCAM1 expression • JAK3 mutation • CD4 expression
    1year
    The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia (ASH 2023)
    The unique subtype of AUL is associated with a particularly adverse risk genotype, irrespective of known prognostic determinants, as in the 2022 ELN classification.
    Clinical
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD36 (thrombospondin receptor) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule) • CD7 (CD7 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ITGAX (Integrin Subunit Alpha X)
    |
    TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • JAK2 mutation • NCAM1 expression • FLT3 expression • FLT3-ITD expression
    1year
    Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies (ASH 2023)
    In conclusion, our data suggest CD56 levels as an important determinant of sensitivity to DARA-based therapies. Moreover, our results suggest the next-generation NAMPT inhibitors as an additional therapeutic strategy for CD56-expressing MM patients.
    Clinical • IO biomarker
    |
    CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    CD38 expression • NCAM1 expression • CD5 overexpression • NCAM1 overexpression • NCAM1 positive
    |
    Darzalex (daratumumab)
    1year
    Integrated Analysis of KIT Exon 17 Mutations and Flow-MRD Refines Risk Stratification in Pediatric Acute Myeloid Leukemia with RUNX1::RUNX1T1 (ASH 2023)
    Patients with both non-mutated KIT exon 17 and negative MRD have the best prognosis, while positive MRD and KIT exon 17 mutations are associated with poorer outcomes. These findings indicated that integrated analysis of flow-MRD and KIT exon 17 status enables optimal risk assignment strategies in pediatric AML with RUNX1::RUNX1T1.
    Clinical
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CD33 (CD33 Molecule) • ARID1B (AT-Rich Interaction Domain 1B) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NRAS mutation • KIT mutation • CD19 expression • KIT exon 17 mutation • ARID1B mutation • NCAM1 expression • CD33 expression
    1year
    Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients (ASH 2023)
    The novel, all-oral combination of Rux+Ven in R/R AML patients was well-tolerated with no DLTs and an encouraging 63% CBR over cycles 1-2. Negative CD56 was a biomarker of response, although additional work is required to determine if this is a broad association with Ven-based therapies or unique to the Rux+Ven combination. The tolerable toxicity profile of Rux+Ven makes it a promising combination to test with HMAs in high-risk AML patients.
    Clinical • P1 data • Combination therapy
    |
    TP53 (Tumor protein P53) • NCAM1 (Neural cell adhesion molecule 1)
    |
    TP53 mutation • NCAM1 expression
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)